Cargando…

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases

Detalles Bibliográficos
Autores principales:	Peterlin, Pierre, Guillaume, Thierry, Garnier, Alice, Le Bourgeois, Amandine, Mahé, Beatrice, Dubruille, Viviane, Blin, Nicolas, Gallas, Pierre, Touzeau, Cyrille, Gastinne, Thomas, Lok, Anne, Thomare, Patrick, Chauvin, Cecile, Le Gouill, Steven, Moreau, Philippe, Chevallier, Patrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993265/ https://www.ncbi.nlm.nih.gov/pubmed/29892542 http://dx.doi.org/10.1016/j.lrr.2018.01.002

Ejemplares similares

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies
por: Chevallier, Patrice, et al.
Publicado: (2018)

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
por: Chevallier, Patrice, et al.
Publicado: (2021)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy
por: Gastinne, Thomas, et al.
Publicado: (2021)

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2022)

Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft
por: Jullien, Maxime, et al.
Publicado: (2020)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia
por: Peterlin, Pierre, et al.
Publicado: (2020)

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
por: Clemenceau, Beatrice, et al.
Publicado: (2021)

Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response
por: Makanga, Dhon Roméo, et al.
Publicado: (2021)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
por: Le Calvez, Baptiste, et al.
Publicado: (2020)

Post‐transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced‐intensity conditioning allotransplant
por: Bourgeois, Amandine Le, et al.
Publicado: (2023)

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

P534: FIRST-IN-HUMAN TRIAL OF TOCILIZUMAB IN COMBINATION WITH A STANDARD INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS: THE PHASE 1 TOCILAM STUDY.
por: Peterlin, Pierre, et al.
Publicado: (2023)

Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft
por: Garnier, Alice, et al.
Publicado: (2022)

Efficacy of anti‐severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation
por: Garnier, Alice, et al.
Publicado: (2022)

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
por: Jullien, Maxime, et al.
Publicado: (2022)

Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in AML patients
por: Peterlin, Pierre, et al.
Publicado: (2022)

Assessment of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients
por: Peterlin, Pierre, et al.
Publicado: (2023)

Incidence and Severity of COVID-19 Infections in a Cohort of 211 Allotransplanted Patients after One or Two Boosters during the Omicron Wave in France
por: Letailleur, Valentin, et al.
Publicado: (2022)

Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients
por: Clemenceau, Beatrice, et al.
Publicado: (2022)

Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial
por: Peterlin, Pierre, et al.
Publicado: (2023)

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide
por: Jullien, Maxime, et al.
Publicado: (2021)

Talk given at the 20th Meeting of the DELPHI Channel Standardization Group
por: Kesterman, J, et al.
Publicado: (1984)

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma
por: Benaniba, Lina, et al.
Publicado: (2019)

DELPHI Progress Report, Transparencies given at LEPC Meeting, 20 March 1985
por: Amaldi, U
Publicado: (1985)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

FDG-PET in Follicular Lymphoma Management
por: Bodet-Milin, C., et al.
Publicado: (2012)

Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study
por: Vantyghem, Sophie, et al.
Publicado: (2020)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy
por: Le Calvez, Baptiste, et al.
Publicado: (2022)

Réunion coordination technique SI N°20
por: Chevallier, G
Publicado: (1970)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients
por: Bohelay, Gérôme, et al.
Publicado: (2022)

Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20
por: Winiarska, Magdalena, et al.
Publicado: (2008)

The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations
por: Mishima, Y, et al.
Publicado: (2011)

Alimentations stabilisees 50A 20V
por: Bourgeois, M
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_1kn4uc3n3iord4ihm7vjkmddhm